Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 6Phase 3 4Phase 1/2 4Phase 4 1

Status

Completed 5Terminated 1

Sponsor Class

NIH 3INDUSTRY 2OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 3Lymphoid 2Sarcoma 1Plasma cell 1Myeloid 1Genitourinary 1CNS 1

Conditions

Multiple Myeloma 69Lymphoma 20Lymphoma, Mantle-Cell 19Leukemia, Myeloid, Acute 17Leukemia, Lymphocytic, Chronic, B-Cell 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma, Non-Hodgkin 15Neoplasms, Plasma Cell 14Lymphoma, Large B-Cell, Diffuse 14Lymphoma, Follicular 13Lymphoma, B-Cell, Marginal Zone 12Unspecified Adult Solid Tumor, Protocol Specific 10Hodgkin Disease 10Lymphoma, Large-Cell, Anaplastic 9Immunoblastic Lymphadenopathy 9Waldenstrom Macroglobulinemia 8Recurrence 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia 8Burkitt Lymphoma 8Myelodysplastic Syndromes 7Lymphoma, T-Cell, Cutaneous 7Head and Neck Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Sezary Syndrome 6Neoplasms 6Mycosis Fungoides 6Lymphoma, Large-Cell, Immunoblastic 6Congenital Abnormalities 6Breast Neoplasms 6

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Bortezomib × Clear all
NCT02211755 2026-04-28

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
28 enrolled
LymphoidMyeloid

Lymphoma, Myelodysplastic Syndromes, Neoplasms

NCT01132911 2017-07-02

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
5 enrolled
CNSGenitourinaryLymphoidSarcoma

Lymphoma, Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma

NCT00891033 2015-02-23

Panobinostat/Velcade in Multiple Myeloma

University of Arkansas

Phase 1 Terminated
12 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

NCT00091117 2013-12-16

Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
80 enrolled
Tumor-Agnostic

Neoplasms

NCT00298779 2008-06-06

Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
20 enrolled
Tumor-Agnostic

Neoplasms

NCT00129207 2008-02-11

Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡